Trial Profile

A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Effect of RC108-ADC for Injection in Subjects with C-Met Positive Advanced Malignant Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 29 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RC 108 (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors RemeGen

Most Recent Events

27 Jan 2025 Status changed from recruiting to active, no longer recruiting.
26 Jun 2023 According to an Innovent Biologics media release, RemeGen received approval from the National Medical Products Administration to conduct Phase 1 clinical trials of RC108 targeting c-MET-positive advanced solid tumors in China.
18 Apr 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com